Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
26.10
-1.90 (-6.79%)
Jun 25, 2025, 4:00 PM - Market closed
Bright Minds Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts that cover Bright Minds Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $83.25, which forecasts a 218.97% increase in the stock price over the next year. The lowest target is $75 and the highest is $93.
Price Target: $83.25 (+218.97%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 21, 2025.
Analyst Ratings
The average analyst rating for Bright Minds Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $80 | Strong Buy | Maintains | $80 | +206.51% | May 21, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | May 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +206.51% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $85 | Strong Buy | Reiterates | $85 | +225.67% | Feb 19, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $93 | Buy | Initiates | $93 | +256.32% | Jan 23, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.